{
    "id": "6025e2641cb411341a0000bb",
    "question": "Can thiotepa be recommended for treatment of osteosarcoma?",
    "options": {
        "A": "yes",
        "B": "no"
    },
    "answer": "B",
    "predict": "{\"step_by_step_thinking\": \"To determine if thiotepa can be recommended for the treatment of osteosarcoma, let's analyze the given documents. According to Document [29], thiotepa is one of the agents used in various regimens to treat malignant diseases, including osteosarcoma. The documents do not explicitly state that thiotepa is contraindicated for osteosarcoma treatment. However, it is essential to consider the potential benefits and side effects of thiotepa in the context of osteosarcoma treatment. Document [29] mentions that most regimens include agents with high activity against the tumor at conventional doses and myelosuppression as their predominant dose-limiting toxicity. Thiotepa is known to have myelosuppressive effects, which may be a concern in osteosarcoma treatment. Furthermore, Document [30] mentions that thiotepa can be associated with prolonged and severe neutropenia, thrombocytopenia, and hepatic toxic effects. These side effects may impact the patient's overall health and quality of life. Considering these factors, while thiotepa may be used in osteosarcoma treatment, its potential side effects and the availability of alternative agents with fewer side effects should be carefully weighed. The decision to recommend thiotepa for osteosarcoma treatment should be made on a case-by-case basis, taking into account the individual patient's needs and medical history. In general, it is essential to consider the potential benefits of thiotepa in combination with other agents and to monitor patients closely for any adverse effects.\", \"answer_choice\": \"A\"}",
    "snippets": [
        {
            "id": "InternalMed_Harrison_7686",
            "title": "InternalMed_Harrison",
            "content": "Stage IIB T2 N0 M0 G3,4 high grade chemotherapy. Pathologic diagnosis is established either with a core-needle biopsy, where feasible, or with an open biopsy with an appropriately placed incision that does not compromise future limb-sparing resection. Most osteosarcomas are high-grade. The most important prognostic factor for long-term survival is response to chemotherapy. Preoperative chemotherapy followed by limb-sparing surgery (which can be accomplished in >80% of patients) followed by postoperative chemotherapy is standard management. The effective drugs are doxorubicin, ifosfamide, cisplatin, and high-dose methotrexate with leucovorin rescue. The various combinations of these agents that have been used have all been about equally successful. Long-term survival rates in extremity osteosarcoma range from 60 to 80%. Osteosarcoma is radioresistant; radiation therapy has no role in the routine management. UPS is considered a part of the spectrum of osteosarcoma and is managed"
        },
        {
            "id": "Pediatrics_Nelson_3400",
            "title": "Pediatrics_Nelson",
            "content": "The current treatment of osteosarcoma involves neoadjuvant chemotherapy followed by surgery and adjuvant chemotherapy. Agents effective against osteosarcoma are doxorubicin, cisplatin, high-dose methotrexate, ifosfamide, and etoposide. The treatment for Ewing sarcoma is similar to that for osteosarcoma; preoperative chemotherapy is given, followed by local control measures, and then further chemotherapy. In contrast to osteosarcoma, Ewing sarcoma is radiation sensitive. Chemotherapy includes vincristine, cyclophosphamide, ifosfamide, etoposide, and doxorubicin."
        },
        {
            "id": "InternalMed_Harrison_7687",
            "title": "InternalMed_Harrison",
            "content": "osteosarcoma range from 60 to 80%. Osteosarcoma is radioresistant; radiation therapy has no role in the routine management. UPS is considered a part of the spectrum of osteosarcoma and is managed similarly."
        },
        {
            "id": "Surgery_Schwartz_4869",
            "title": "Surgery_Schwartz",
            "content": "registry, J Surg Res. 2007;141(1):105-114.Table 19-24Classification of sarcomas by therapeutic responseTUMOR TYPECHEMOTHERAPY SENSITIVITYOsteosarcoma+Rhabdomyosarcoma+Primitive neuroectodermal tumor+Ewing\u2019s sarcoma+Malignant fibrous histiocytoma\u00b1Fibrosarcoma\u00b1Liposarcoma\u00b1Synovial sarcoma\u00b1sometimes in association with previous radiation, Paget\u2019s disease, or chemotherapy. Radiographically, the typical appearance consists of spicules of new periosteal bone formation producing a sunburst appearance. Osteosarcomas have a propensity to spread to the lungs, and up to one-third of patients present with metastatic disease. Osteosarcomas are potentially sensitive to chemotherapy. Currently, pre-operative chemotherapy is common. After chemotherapy, complete resection is performed with wide (4-cm) margins, followed by reconstruction. In patients presenting with lung metastases that are potentially amenable to surgical resection, induction chemotherapy may be given, followed by surgical resection"
        },
        {
            "id": "First_Aid_Step2_552",
            "title": "First_Aid_Step2",
            "content": "Constitutional symptoms such as fever, weight loss, and night sweats may be present. Erythema and enlargement over the site of the tumor may be seen. See the Endocrinology chapter for a discussion of osteosarcoma vs. Paget\u2019s disease. Radiographs show Codman\u2019s triangle (periosteal new bone formation at the diaphyseal end of the lesion) or a \u201csunburst pattern\u201d of the osteosarcoma (see Figure 2.9-3)\u2014in contrast to multilayered \u201conion skinning,\u201d which is classic for Ewing\u2019s sarcoma. MRI and CT facilitate staging (soft tissue and bony invasion) and planning for surgery. Limb-sparing surgical procedures and preand postoperative chemotherapy (e.g., methotrexate, doxorubicin, cisplatin, ifosfamide). Amputation may be necessary. A common, chronic, nonin\ufb02 ammatory arthritis of the synovial joints. Characterized by deterioration of the articular cartilage and osteophyte bone formation at the joint surfaces. Risk factors include a family history, obesity, and a history of joint trauma."
        },
        {
            "id": "InternalMed_Harrison_7682",
            "title": "InternalMed_Harrison",
            "content": "Osteosarcoma, accounting for almost 45% of all bone sarcomas, is a spindle cell neoplasm that produces osteoid (unmineralized bone) or bone. Approximately 60% of all osteosarcomas occur in children and adolescents in the second decade of life, and approximately 10% occur in the third decade of life. Osteosarcomas in the fifth and sixth decades of life are frequently secondary to either radiation therapy or transformation in a preexisting benign condition, such as Paget\u2019s disease. Males are affected 1.5\u20132 times as often as females. Osteosarcoma has a predilection for metaphyses of long bones; the most common sites of involvement are the distal femur, proximal tibia, and proximal humerus. The classification of osteosarcoma is complex, but 75% of osteosarcomas fall into the \u201cclassic\u201d category, which include osteoblastic, chondroblastic, and fibroblastic osteosarcomas. The remaining 25% are classified as \u201cvariants\u201d on the basis of (1) clinical characteristics, as in the case of"
        },
        {
            "id": "Pediatrics_Nelson_3394",
            "title": "Pediatrics_Nelson",
            "content": "Osteosarcoma often is located at the epiphysis or metaphysis of anatomic sites that are associated with maximum growth velocity (distal femur, proximal tibia, proximal humerus), but any bone may be involved. It presents with pain and may be associated with a palpable mass. Because the pain and swelling often are initially thought to be related to trauma, radio-graphs of the affected region frequently are obtained, which usually reveal a lytic lesion, often associated with calcification in the soft tissue surrounding the lesion. While 75% to 80% of patients with osteosarcoma have apparently localized disease at diagnosis, the majority of patients are believed to have micrometastatic disease as well. Although Ewing sarcoma can occur in almost any bone in the body, the femur and pelvis are the most common sites. In addition to local pain and swelling, clinical manifestations may include systemic symptoms, such as fever and weight loss."
        },
        {
            "id": "Pathology_Robbins_4803",
            "title": "Pathology_Robbins",
            "content": "Osteosarcoma is treated with a multimodality approach that consists of (1) neoadjuvant chemotherapy, (2) surgery, and (3) chemotherapy. The amount of chemotherapy-induced necrosis found at surgical resection is an important prognostic finding. These aggressive neoplasms spread hematogenously to the lungs. Although the prognosis has improved substantially since the advent of chemotherapy, with 5-year survival rates reaching 60% to 70% in patients without detectible metastases at initial diagnosis, the outcome for patients with metastases, recurrent disease, or secondary osteosarcoma is still poor. Fig.21.18Fine,lacelikepatternofneoplasticboneproducedbyanaplasticmalignanttumorcellsinanosteosarcoma.Notetheabnormalmitoticfigure(arrow). These tumors are characterized by the formation of hyaline cartilage. Benign cartilaginous tumors are much more common than malignant ones."
        },
        {
            "id": "Pediatrics_Nelson_3397",
            "title": "Pediatrics_Nelson",
            "content": "Definitive diagnosis of osteosarcoma often is establishedby carefully placed needle biopsy. The presence of osteoidand immunohistochemical analysis confirms the diagnosisof osteosarcoma. The extent of the primary tumor shouldbe delineated carefully with magnetic resonance imaging(MRI) before starting chemotherapy. Osteosarcoma tends tometastasize to the lung, most commonly, and rarely to otherbones. Metastatic evaluation includes a chest CT scan and a bone scan. The diagnosis of Ewing sarcoma is established with immunohistochemical analysis and cytogenetic and molecular diagnostic studies of the biopsy material. Ewing sarcoma is characterized by a specific chromosomal translocation, t(11;22), which is seen in 95% of tumors. MRI of the primary lesion should be performed to delineate extent of the lesion and any associated soft tissue mass. Metastatic evaluation involves a bone scan, chest CT scan, and bone marrow aspiration and biopsy."
        },
        {
            "id": "Pathology_Robbins_4798",
            "title": "Pathology_Robbins",
            "content": "Osteosarcoma is a malignant tumor that produces osteoid matrix or mineralized bone. Excluding hematopoietic tumors (myeloma and lymphoma), osteosarcoma is the most common primary malignant tumor of bone. Osteosarcoma has a bimodal age distribution; 75% of osteosarcomas occur in persons younger than 20 years of age. The smaller second peak occurs in older adults, who frequently suffer from conditions known to predispose to osteosarcoma, such as Paget disease, bone infarcts, and previous radiation. These are referred to as secondary osteosarcomas. Overall, men are more commonly affected than women (1.6:1). The most common sites in adolescents are the metaphyseal regions of the distal femur and proximal tibia. Osteosarcomas present as painful, progressively enlarging masses. Sometimes a pathologic fracture is the first indication. Radiographs usually show a large, destructive, mixed lytic and sclerotic mass with infiltrative margins ("
        },
        {
            "id": "Surgery_Schwartz_12608",
            "title": "Surgery_Schwartz",
            "content": "the tumor and the host bone since this margin can also indicate the aggres-siveness of the tumor. Ewing\u2019s sarcoma has a characteristic \u201conion skin\u201d periosteal reaction pattern. This reaction pattern also occurs in other tumors and infections.OSTEOSARCOMAThe most common primary malignant bone tumor is osteosar-coma (Fig. 43-44). Osteosarcomas are classified as osteoblas-tic, chondroblastic, fibroblastic, telangiectatic, round cell, or MFH-like, according to the predominant cell type. Most osteo-sarcomas present in patients between 10 and 20 years of age. Secondary osteosarcomas occur in older patients in abnormal bone affected by Paget\u2019s disease, radiation, or bone infarct.Intramedullary OsteosarcomaThis is the most common primary sarcoma of the bone. It usu-ally occurs in the distal femur or the proximal tibia in young people. This condition may also occur at the proximal humerus, proximal femur, or pelvis. It usually presents itself as a high-grade extracompartmental disease. It can"
        },
        {
            "id": "Pediatrics_Nelson_3402",
            "title": "Pediatrics_Nelson",
            "content": "For all children with sarcoma, presence or absence of metastatic disease at presentation is the most important prognostic factor. The outlook remains poor for patients who have distant metastasis from Ewing sarcoma, rhabdomyosarcoma, or osteosarcoma at diagnosis. Patients with localized rhabdomyosarcomas in favorable sites have an excellent prognosis when treated with surgery followed by vincristine and actinomycin. In patients with osteosarcoma and Ewing sarcoma, another important prognostic factor is the degree of tumor necrosis after preoperative chemotherapy. In general, patients whose tumor specimens show a high degree (>90%) of necrosis following preoperative chemotherapy have an event-free survival rate greater than 80%. Patients who still have large amounts of viable tumor after presurgical chemotherapy have a much worse prognosis. The cure rate for patients with localized osteosarcoma and Ewing sarcoma is approximately 60% to 70%. Patients who have lung metastasis at"
        },
        {
            "id": "Pediatrics_Nelson_3403",
            "title": "Pediatrics_Nelson",
            "content": "after presurgical chemotherapy have a much worse prognosis. The cure rate for patients with localized osteosarcoma and Ewing sarcoma is approximately 60% to 70%. Patients who have lung metastasis at diagnosis have a cure rate of approximately 30% to 35%. Patients with metastases to other bones have a poor prognosis."
        },
        {
            "id": "First_Aid_Step2_975",
            "title": "First_Aid_Step2",
            "content": "Presents as an asymptomatic, nontender, smooth abdominal mass. Abdominal pain, fever, hypertension, and microscopic or gross hematuria are seen. CBC, BUN, creatinine, and UA. Abdominal ultrasound. CT scans of the chest and abdomen are used to detect metastases. Local resection and nephrectomy with postsurgical chemotherapy and radiation depending on stage and histology. It is critical to distinguish between Ewing\u2019s sarcoma and osteosarcoma (see Table 2.13-10). An important aspect of every well-child visit. Commonly tested advice includes the following: T AB LE 2.1 3-1 0. Ewing\u2019s Sarcoma vs. Osteosarcoma"
        },
        {
            "id": "Surgery_Schwartz_12612",
            "title": "Surgery_Schwartz",
            "content": "the definitive treatment for the patient. Treatment of osteosarcoma will be preoperative chemotherapy and wide resection, followed by postoperative chemotherapy.Parosteal OsteosarcomaParosteal osteosarcoma is a low-grade surface osteosarcoma that appears as if it were stuck on the bone, especially in the pos-terior distal femoral metaphysis (80%). The differential diagno-sis includes osteochondroma and myositis ossificans. Treatment consists of wide excision. The prognosis is 95% 5-year survival as it is a low-grade tumor.Periosteal OsteosarcomaPeriosteal osteosarcoma is a high-grade tumor. It occurs on the anterior surface of the distal femur or proximal tibia. The lesion appears chondroblastic on histology. Radiographs show scalloping of the underlying cortex with a \u201csunburst\u201d periosteal reaction. Treatment is chemotherapy and wide surgical excision. The 5-year survival rate is 80%.Paget\u2019s SarcomaPaget\u2019s sarcoma is a rare complication of Paget\u2019s disease. In Paget\u2019s disease with"
        },
        {
            "id": "Pharmacology_Katzung_5961",
            "title": "Pharmacology_Katzung",
            "content": "Doxorubicin is one of the most important anti-cancer drugs in clinical practice, with major clinical activity in cancers of the breast, endometrium, ovary, testicle, thyroid, stomach, bladder, liver, and lung; in soft tissue sarcomas; and in several childhood cancers, including neuroblastoma, Ewing\u2019s sarcoma, osteosarcoma, and rhabdomyosarcoma. It also has clinical activity in hematologic malignancies, including acute lymphoblastic leukemia, multiple myeloma, and Hodgkin\u2019s and non-Hodgkin\u2019s lymphomas. It is generally used in combination with other anti-cancer agents (eg, cyclophosphamide, cisplatin, and 5-FU), and clinical activity is improved with combination regimens as opposed to single-agent therapy. Daunorubicin was the first agent in this class to be isolated, and it is still used in the treatment of acute myeloid leukemia. In contrast to doxorubicin, its efficacy in solid tumors is limited."
        },
        {
            "id": "Surgery_Schwartz_12611",
            "title": "Surgery_Schwartz",
            "content": "10:41 AM 1912SPECIFIC CONSIDERATIONSPART IItumor after chemotherapy is a good sign) and the stage of the disease determines the prognosis. Young patients may present with pain and swelling, with X-rays showing plastic lesions in some areas of destruction with periosteal reaction called \u201cCodman\u2019s Triangle.\u201d X-rays may show bone formation with a sunburst appearance. MRI should involve the entire bone to diagnose the skip metastasis. CT scans of the chest are usually done to find primary metastases. Alkaline phosphatase is usu-ally high. Diagnosis is typically confirmed with a biopsy, which is done after staging the tumor. Proper biopsy technique should be employed, which includes longitudinal incisions. As a gen-eral rule, the biopsy should be done by the same surgeon who will provide the definitive treatment for the patient. Treatment of osteosarcoma will be preoperative chemotherapy and wide resection, followed by postoperative chemotherapy.Parosteal OsteosarcomaParosteal"
        },
        {
            "id": "InternalMed_Harrison_7683",
            "title": "InternalMed_Harrison",
            "content": "category, which include osteoblastic, chondroblastic, and fibroblastic osteosarcomas. The remaining 25% are classified as \u201cvariants\u201d on the basis of (1) clinical characteristics, as in the case of osteosarcoma of the jaw, postradiation osteosarcoma, or Paget\u2019s osteosarcoma; (2) morphologic characteristics, as in the case of telangiectatic osteosarcoma, small-cell osteosarcoma, or epithelioid osteosarcoma; or (3) location, as in parosteal or periosteal osteosarcoma. Diagnosis usually requires a synthesis of clinical, radiologic, and pathologic features. Patients typically present with pain and swelling of the affected area. A plain radiograph reveals a destructive lesion with a moth-eaten appearance, a spiculated periosteal reaction (sunburst appearance), and a cuff of periosteal new bone formation at the margin of the soft tissue mass (Codman\u2019s triangle). A CT scan of the primary tumor is best for defining bone destruction and the pattern of calcification, whereas MRI is better for"
        },
        {
            "id": "Surgery_Schwartz_4866",
            "title": "Surgery_Schwartz",
            "content": "chest wall likely to be a low-grade chondrosarcoma should be treated with wide (4-cm) resection after metastatic disease to the lungs or bones is ruled out. Chondrosarcomas are not sensitive to radiation or chemo-therapy. Prognosis is determined by tumor grade and extent of resection. With a low-grade tumor and wide resection, patient survival at 5 to 10 years can be as high as 60% to 80%.2. Osteosarcoma. While osteosarcomas are the most com-mon bone malignancy, they represent only 10% to 15% of all malignant chest wall tumors.133,134 They primarily occur in young adults as rapidly enlarging, painful masses; how-ever, osteosarcomas can occur in older patients as well, Figure 19-40. Chest computed tomography scan showing a right chest wall tumor (arrow). Tissue diagnosis revealed that this mass was a leiomyosarcoma.Brunicardi_Ch19_p0661-p0750.indd 72301/03/19 7:01 PM 724SPECIFIC CONSIDERATIONSPART IITable 19-23Cox proportional hazards model for risk of death from soft tissue"
        },
        {
            "id": "Pediatrics_Nelson_3391",
            "title": "Pediatrics_Nelson",
            "content": "The cause is unknown for most children diagnosed with sarcoma, although a few observations have been made regarding risks. Individuals with Li-Fraumeni syndrome (associated with a germline p53 mutation) and neurofibromatosis (associated with NF1 mutations) have an increased risk of softtissue sarcomas. There is a 500-fold increased risk for osteosarcoma for individuals with hereditary retinoblastoma. Prior treatment for childhood cancer with radiation therapy or chemotherapy, specifically alkylating agents, or both, increases the risk for osteosarcoma as a second malignancy."
        },
        {
            "id": "Pathology_Robbins_4799",
            "title": "Pathology_Robbins",
            "content": "Fig. 21.16 ). The tumor frequently breaks through the cortex and lifts the periosteum, resulting in reactive subperiosteal bone formation. The triangular shadow between the cortex and raised ends of periosteum, known radiographically as Codman triangle, is indicative of an aggressive tumor, but is not pathognomonic of osteosarcoma. Approximately 70% of osteosarcomas have acquired genetic abnormalities such as complex structural and numerical chromosomal aberrations. Molecular studies have shown that these tumors usually have mutations in well-known tumor suppressors and oncogenes: \u2022 RB is a critical negative regulator of the cell cycle. Patients with germline mutations in RB have a 1000-fold increased risk of osteosarcoma, and somatic RB mutations are present in up to 70% of sporadic osteosarcomas. Fig.21.15Osteoidosteomacomposedofhaphazardlyinterconnectingtra-beculaeofwovenbonethatarerimmedbyprominentosteoblasts.Theintertrabecularspacesarefilledbyvascularizedlooseconnectivetissue."
        },
        {
            "id": "Surgery_Schwartz_10539",
            "title": "Surgery_Schwartz",
            "content": "of adriamycin in human neoplasia. Cancer. 1977;39:1940-1948. 128. Patel SR, Vadhan-Raj S, Papadopolous N, et al. High-dose ifosfamide in bone and soft tissue sarcomas: results of phase II and pilot studies\u2014dose-response and schedule dependence. J Clin Oncol. 1997;15:2378-2384. 129. Movva S, Verschraegen C. Systemic management strategies for metastatic soft tissue sarcoma. Drugs. 2011;71:2115-2129. 130. Patel SR, Gandhi V, Jenkins J, et al. Phase II clinical investi-gation of gemcitabine in advanced soft tissue sarcomas and window evaluation of dose rate on gemcitabine triphosphate accumulation. J Clin Oncol. 2001;19:3483-3489. 131. Hensley ML, Maki R, Venkatraman E, et al. Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial. J Clin Oncol. 2002;20:2824-2831. 132. Dileo P, Morgan JA, Zahrieh D, et al. Gemcitabine and vinorelbine combination chemotherapy for patients with advanced soft tissue sarcomas: results of a phase II trial. Cancer."
        },
        {
            "id": "Surgery_Schwartz_10417",
            "title": "Surgery_Schwartz",
            "content": "studies are warranted for this promising combination of agents.141Benefits of Systemic Therapy. The use of adjuvant and neoad-juvant chemotherapy for soft tissue sarcomas remains controver-sial. More than a dozen individual randomized trials of adjuvant chemotherapy have failed to demonstrate improvement in disease-free or overall survival for patients with soft tissue sarcoma. How-ever, several limitations of these individual trials may explain the lack of observed improvement. First, the chemotherapy regimens used were suboptimal, consisting of single-agent therapy (most commonly with doxorubicin) and insufficiently intensive dosing schedules. Second, the patient groups were not large enough to reveal clinically significant differences in survival rates. Finally, most studies included patients at low risk of metastasis and death, namely those with small (<5 cm) and low-grade tumors.The Sarcoma Meta-Analysis Collaboration analyzed 1568 patients from 14 trials of doxorubicin-based"
        },
        {
            "id": "Surgery_Schwartz_10544",
            "title": "Surgery_Schwartz",
            "content": "Van Glabbeke M, Hohenberger P, et al. Adjuvant chemotherapy (CT) with doxorubicin and ifosfamide in resected soft tissue sarcoma (STS): interim analysis of a randomised phase III trial. J Clin Oncol. 2007;25:10008. 149. O\u2019Connor J, Chac\u00f3n M, Petracci F, et al. Adjuvant chemother-apy in soft tissue sarcoma (STS): a meta-analysis of published data. ASCO Meeting Abstracts, 2008, Abstract 10526. 150. Pervaiz N, Colterjohn N, Farrokhyar F, et al. A systematic meta-analysis of randomized controlled trials of adjuvant chemotherapy for localized resectable soft-tissue sarcoma. Cancer. 2008;113:573-581. 151. Eilber FC, Tap WD, Nelson SD, et al. Advances in chemo-therapy for patients with extremity soft tissue sarcoma. Orthop Clin North Am. 2006;37:15-22. 152. Gronchi A, Frustaci S, Mercuri M, et al. Short, full-dose adju-vant chemotherapy in high-risk adult soft tissue sarcomas: a randomized clinical trial from the Italian Sarcoma Group and the Spanish Sarcoma Group. J Clin Oncol."
        },
        {
            "id": "Surgery_Schwartz_2289",
            "title": "Surgery_Schwartz",
            "content": "the basis of World Health Organization standard criteria.146 Significant drug toxicity may necessitate a dosage reduction. A toxic effect requiring a dose modification or change in dose intensity is referred to as a dose-limiting toxic effect. Because maintaining dose intensity is important to preserve as high a tumor cell kill as possible, several supportive strategies have been developed, such as administration of colony-stimulating factors and erythropoietin to treat poor bone marrow reserve and administration of cytoprotectants such as mesna and amifostine to prevent renal dysfunction. Some toxicities, such as neuropa-thy, are not as easily reversible, and their potential effects on lifestyle must be considered when evaluating a patient prior to the initiation of chemotherapy.Administration of ChemotherapyChemotherapy usually is administered systemically (IV, IM, SC, or PO). Systemic administration treats micrometastases at widespread sites and prevents systemic recurrence."
        },
        {
            "id": "Pathology_Robbins_4801",
            "title": "Pathology_Robbins",
            "content": "CDKN2A is inactivated in many osteosarcomas. This gene encodes two tumor suppressors, p16 (a negative regulator of cyclin-dependent kinases) and p14 (which augments p53 function). MDM2 and CDK4, which are cell cycle regulators that inhibit p53 and RB function, respectively, are overexpressed in many low-grade osteosarcomas. It also is noteworthy that osteosarcomas peak in incidence around the time of the adolescent growth spurt and occur most frequently in the region of the growth plate in bones with the fastest growth. The increased proliferation at these sites may predispose to osteosarcoma development. MORPHOLOGYOsteosarcomasarebulkytumorsthataregritty,gray-white,andoftencontainareasofhemorrhageandcysticdegeneration( Fig.21.17 ).Thetumorsfrequentlydestroythesurroundingcorticesandproducesofttissuemasses.Theyspreadextensivelyinthemedullarycanal,infiltratingandreplacingthemarrow. http://ebooksmedicine.net"
        },
        {
            "id": "Pathology_Robbins_1444",
            "title": "Pathology_Robbins",
            "content": "http://ebooksmedicine.net In most instances, the laboratory diagnosis of cancer is not difficult. The two ends of the benign\u2013malignant spectrum pose no problems; in the middle, however, lies a \u201cno man\u2019s land\u201d where the wise tread cautiously. Clinicians tend to underestimate the contributions they make to the diagnosis of a neoplasm. Clinical and radiologic data are invaluable for optimal pathologic diagnosis. Radiation-induced changes in the skin or mucosa can be similar to those of cancer. Sections taken from a healing fracture can mimic an osteosarcoma. The laboratory evaluation of a lesion can be only as good as the specimen submitted for examination. The specimen must be adequate, representative, and properly preserved."
        },
        {
            "id": "Surgery_Schwartz_10538",
            "title": "Surgery_Schwartz",
            "content": "CP, Ballo MT, Zagars GK, et al. Complications of combined modality treatment of primary lower extremity soft-tissue sarcomas. Cancer. 2006;107:2455-2461. 124. Stinson SF, DeLaney TF, Greenberg J, et al. Acute and long-term effects on limb function of combined modality limb sparing therapy for extremity soft tissue sarcoma. Int J Radiat Oncol Biol Phys. 1991;21:1493-1499. 125. Kepka L, DeLaney TF, Suit HD, Goldberg SI. Results of radia-tion therapy for unresected soft-tissue sarcomas. Int J Radiat Oncol Biol Phys. 2005;63(3):852-859. 126. Ferrari A, Gronchi A, Casanova M, et al. Synovial sarcoma: a retrospective analysis of 271 patients of all ages treated at a single institution. Cancer. 2004;101:627-634. 127. O\u2019Bryan RM, Baker LH, Gottlieb JE, et al. Dose response evaluation of adriamycin in human neoplasia. Cancer. 1977;39:1940-1948. 128. Patel SR, Vadhan-Raj S, Papadopolous N, et al. High-dose ifosfamide in bone and soft tissue sarcomas: results of phase II and pilot"
        },
        {
            "id": "Pathology_Robbins_4910",
            "title": "Pathology_Robbins",
            "content": "Seamon J, Keller T, et al: The pathogenesis of nontraumatic osteonecrosis, Arthritis 601763, 2012. [Summarizes recent developments regarding pathophysiology of femoral head osteonecrosis.] Klein MJ, Siegal GP: Osteosarcoma: anatomic and histologic variants, Am J Clin Pathol 125:555\u2013581, 2006. [Most recent update on classification of osteosarcoma.] Wagner ER, Luther G, Zhu G, et al: Defective osteogenic differentiation in the development of osteosarcoma, Sarcoma 2011:325238, http://ebooksmedicine.net 2011. [Discusses molecular relationship between normal osteoblast development the pathogenesis of osteosarcoma.] Bovee JV, Hogendoorn PC, Wunder JS, et al: Cartilage tumours and bone development: molecular pathology and possible therapeutic targets, Nat Rev Cancer 10:481\u2013488, 2010. [A good review of the known genetic abnormalities in these tumors]"
        },
        {
            "id": "InternalMed_Harrison_9068",
            "title": "InternalMed_Harrison",
            "content": "to immunosuppress the patient adequately to accept the marrow graft. In the setting of thalassemia and sickle cell anemia, high-dose busulfan is frequently added to cyclophosphamide in order to eradicate hyperplastic host hematopoiesis. A variety of different regimens have been developed to treat malignant diseases. Most of these regimens include agents that have high activity against the tumor in question at conventional doses and have myelosuppression as their predominant dose-limiting toxicity. Therefore, these regimens commonly include busulfan, cyclophosphamide, melphalan, thiotepa, carmustine, etoposide, and total-body irradiation in various combinations."
        },
        {
            "id": "Surgery_Schwartz_10414",
            "title": "Surgery_Schwartz",
            "content": "myxoid liposarcoma, and other translocation-related sarcomas.135 Trabectedin is generally well tolerated but can be associated with prolonged and severe neutropenia, thrombocytopenia, and hepatic toxic effects.Palifosfamide is a stabilized formulation of the active metabolite of ifosfamide that has been reported to be better tolerated than ifosfamide.136 Early trials have suggested anti-tumor activity comparable or superior to that of ifosfamide without nephrotoxicity; however, recent negative results of the PICASSO III Trial, a phase 3, placebo-controlled study of doxorubicin with or without palifosfamide in patients with metastatic soft tissue sarcoma, have neatly secured the fate of palifosfamide in the treatment of soft tissue sarcoma.137Targeted Therapies. Several targeted agents are being investigated for the treatment of soft tissue sarcomas. Among these are tyrosine kinase inhibitors (e.g., imatinib, suni-tinib, sorafenib, and dasatinib) that have been developed and approved"
        },
        {
            "id": "Pathoma_Husain_474",
            "title": "Pathoma_Husain",
            "content": "III. OSTEOCHONDROMA A. Tumor of bone with an overlying cartilage cap (Fig. 18.3); most common benign tumor ofbone B. Arises from a lateral projection of the growth plate (metaphysis); bone is continuous with the marrow space. C. Overlying cartilage can transform (rarely) to chondrosarcoma. IV. OSTEOSARCOMA A. Malignant proliferation of osteoblasts B. Peak incidence is seen in teenagers; less commonly seen in the elderly 1. Risk factors include familial retinoblastoma, Paget disease, and radiation exposure. 2. Arises in the metaphysis of long bones, usually the distal femur or proximal tibia (region of the knee) C. Presents as a pathologic fracture or bone pain with swelling D. Imaging reveals a destructive mass with a 'sunburst' appearance and lifting of the periosteum (Codman triangle, Fig. 18.4A). Fig. 18.3 Osteochondroma. (Courtesy of Fig. 18.4 Osteosarcoma. A, X-ray. B, Microscopic appearance. (A, Courtesy of Bu lent Celasun, MD) humpath.com)"
        }
    ],
    "scores": [
        0.036135640696956746,
        0.03532467155046956,
        0.03497039416887489,
        0.03247293389779385,
        0.025523551865103713,
        0.02509856014528912,
        0.024565315183164155,
        0.024311767044325184,
        0.023882049496803594,
        0.023762301855608143,
        0.023451311154238833,
        0.023310892940626462,
        0.022299629559446976,
        0.021813732882910056,
        0.021769733534439416,
        0.021558825378859333,
        0.02062911388343045,
        0.019142700128228614,
        0.0180999180999181,
        0.017721320473614053,
        0.017621487346685297,
        0.017577673271143318,
        0.017307978012182437,
        0.01727574750830565,
        0.01725393127548049,
        0.016849557522123894,
        0.016797541823147834,
        0.016771929824561403,
        0.0167601683029453,
        0.01628707627118644,
        0.016203703703703703,
        0.016066589237320947
    ]
}